Category: Kinase Inhibitors

In addition to clinical studies and cell line models, several rodent models have been developed to elucidate the mechanisms of CIPN and identify potential therapies, including those that measure pathological, electrophysiological, and behavioral outcomes that mimic CIPN in patients. In particular, studies in cultured rat dorsal root ganglion neurons have provided insight into underlying mechanisms of CIPN. However, clinical trials that relied on preclinical animal data have not resulted in consistent benefits of candidate CIPN treatments. Although pain reduction was observed in a recent trial of duloxetine in patients with CIPN, there are BAY 43-9006 currently no FDA approved treatments for CIPN. Due to the rapid advances in stem cell technology, the ability to differentiate human neurons from iPSCs provides an opportunity to create panels of genetically diverse human neurons. Large quantities of neurons from one iPSC line are commercially available for preliminary assay development, drug screens, siRNA screens or functional studies of candidate genes. Upon treatment of iCell Neurons with increasing concentrations of representative neurotoxic agents, we identified reproducible decreases in neurite outgrowth phenotypes. As a proof of concept, we show that decreased PCI-32765 expression of the paclitaxel target TUBB2A by siRNA transfection causes decreased neurite outgrowth after paclitaxel treatment, as expected based on a previous patient study. We show that the variance in neurite outgrowth phenotypes is greater between individuals than the experimental variance within individuals, demonstrating that larger genetic association studies are possible with iPSC-derived neurons. We have applied a human neuronal cell model to the study of chemotherapeutic neurotoxicity. We demonstrate reproducible differences in morphological changes including neurite outgrowth phenotypes, cellular viability and apoptosis among four distinct chemotherapeutic drugs. Importantly, we identified differences among genetically distinct iPSC-derived neurons in the degree of apoptosis for vincristine and cisplatin, relative number of processes for vincristine and relative total outgrowth, process length, and number of branches for paclitaxel. The iPSC-derived neurons are a highly relevant human model currently available for neurotoxicity and much improved from the LCL model used previously for screening and validation. In the human neuronal model, vincristine was the most neurotoxic as measured by morphological changes following treatment.

The decline in glucose is most likely a result of withholding feed during acclimation and experimentation and the exhaustion of energy stores. Brown et al. reported a similar alteration in plasma glucose in catheterized PI-103 rainbow trout and attributed it to withholding feed. There was no effect of waterborne Mo exposure on hematocrit. The results of this study are in XAV939 in vivo concordance with data from a chronic waterborne exposure of up to 17 mg l-1 reporting no change in hematocrit in various life stages of rainbow trout. Findings outlined by McConnell regarding observations of fused gill lamellae in rainbow trout and by Reid regarding increased ventilation and mucus production in kokanee salmon during Mo exposure, however, would preclude one to think that these manifestations would have an effect on hematocrit. According to Heath, any pollutant that results in gill damage and subsequent internal hypoxia can be expected to increase hematocrit. This indicates that waterborne Mo, despite irritating the gills, does not induce internal hypoxia. This is also true of the metal lead. When Hodson et al. and Martinez et al. exposed rainbow trout and Prochilodus lineatus to waterborne lead they observed that although the metal caused changes in gill morphology hematocrit remained unaffected. Exposure of rainbow trout toMo failed to upregulate expression of hsp72, hsp73, and hsp90. There was no response in the liver, gills, heart, or erythrocytes of juveniles exposed to a maximum of 20 mg l-1 or in the liver or gills of fingerlings exposed to a maximum of 1000 mg l-1. As a result, there appears to be no utility of these proteins as measures ofMo exposure. There is confidence that the lack of induction in response to acuteMo exposure in trout does not reflect a reduced capacity of fish to activate a heat shock response. In this study, heat shocked fish responded by synthesizing hsp72 and in previous studies that used the same antibodies heat shocked fish responded with inductions in hsp72 and hsp90 in rainbow trout liver, heart, and erythrocytes. Heat shock in rainbow trout has also lead to increases in hsp70 mRNA in the liver, gills, heart, and blood. The lack of hsp induction byMo is also not due to metal load sequestering by MT because, as discussed later, there was no induction of MT in response to Mo exposure. Molybdenum is not the only stressor that is incapable of stimulating hsp70 production. Neither anesthesia administration nor handling induced hsp70 levels in the liver, gills, heart, or muscle of rainbow trout.

Despite the fact that the 24-hr deglycosylation reduced the molecular size of the main protein bands of G207 and G208 only by 10% on SDS-PAGE, it produced significant changes in antibacterial activities of these two glycoproteins. The size of the inhibition zones produced by G208 was dependent on concentrations of glps added to the well. Deglycosylation of G208 caused a reduction of the inhibition zones at all three dilutions in comparison to glycosylated G208, although these decreases were not statistically significant. In contrast, G207 produced a zone of inhibition only at its highest concentration, and deglycosylation of G207 resulted in a significant decrease or a complete loss of the antibacterial activity of this glycoprotein. These results established that G207 displayed mostly agglutinating activity for which glycosylation was essential. In contrast, the mechanism by which G208 produced antibacterial Axitinib VEGFR/PDGFR inhibitor effect was not solely glycosylation-dependent. The unsuspected finding of this study was the identification of honey glycoproteins as active principal molecules that caused agglutination and a rapid, concentration-depended WZ8040 bactericidal effect on both Gram-negative E. coli and Gram positive B. subtilis. The presence of high mannose- type of oligosaccharides in honey glycoproteins allowed their selective isolation using resin-immobilized Concavalin A. Subsequently, we have demonstrated that only the high mannose- type glycoproteins retained by ConA-column showed growth inhibitory and bactericidal activities, while flow-through proteins devoid of mannose-rich glycans were unable to inhibit bacterial growth, reduce bacterial viability or influence bacterial cell shape. These results indicated that the high-mannose structures have a significant role in the antibacterial activity of isolated honey glycoproteins. Due to the presence of carbohydrate moiety, glps displayed lectin-like activity, agglutinating both Gram-positive B. subtilis and Gram-negative E. coli. Agglutinating specificity of honey glps was similar to that of ConA. Both, Glps and ConA had much lower lower reactivity with murine red blood cells than phytohemagglutinin, but efficiently agglutinated both E. coli and B. subtilis cells. This supports reports indicating that ConA binds mannose receptors on B. subtilis cell wall peptidoglycans and on E. coli cell envelope with high affinity, but does not recognize branched, complex-type N-glycans, containing galactose on erythrocyte membranes. The binding specificity of ConA and glps allowed the dissociation of agglutinating from hemagglutinating activities.

By fusing a glutathione S-transferase gene to the JAK2 activation loop, we are able to isolate and directly probe for JAK2 phosphorylation of a bona fide JAK2 substrate. Interestingly, some of the identified mutations in TEL-JAK2 did not translate to resistance in Jak2 V617F. We evaluated the entire panel of mutations in the context of Jak2 V617F with XTT-based BKM120 survival, downstream signaling, and with the GST-J2s kinase assay. We observed only JAK2 V617F G935R to display a striking difference in survival, downstream signaling, and substrate phosphorylation in comparison to the wild-type protein and other mutants. There are at least two possible explanations for this finding. First, the difference may be due to the relative kinase strength of TEL-JAK2 compared to Jak2 V617F. The Jak2 V617F allele is not transforming unless it has a functional FERM domain and is provided with a cytokine scaffold, and even then is relatively indolent without other mutations present. In contrast, TEL-JAK2 is a potent oncogene, thought to be causative in some cases of acute myeloid leukemia. Therefore, even small differences in inhibitor resistance will be evident with TELJAK2, while the homologous mutations may have subtle effects in the context of Jak2 V617F. Second, the mechanisms of activation of TEL-JAK2 and Jak2 V617F are different. The PNT dimerization domain of TEL causes oligimerization of the TELJAK2 protein and constitutive activation. Therefore, the inhibitor resistance observed in some TEL-JAK2 mutations may be due to the oligimerization-specific interaction between the kinase domains. In order to understand how the panel of identified mutations contributes to inhibitor resistance, mutations were modeled using the previously published JAK2 kinase domain crystal structure complexed with JAK Inhibitor-I. The unmutated kinase domain residues isolated in the screen are displayed. G935 lies within the hinge region between the WZ8040 N-lobe and C-lobe. The G935R mutation introduces a spatial clash resulting from the arginine side chain, which prevents inhibitor binding. R975 is located in the catalytic loop region connecting a-helix D with the activation loop. The replacement of arginine by glycine, combined with increased flexibility of the main chain, would influence inter-loop interactions, possibly affecting opening of the pocket. E864K results in a change in side chain charge, and would result in a steric clash with a neighboring lysine. This would result in movement of the b-sheet and occlusion of the pocket. N909K introduces a steric clash that may push neighboring V911 into the binding pocket. The V881A mutation will result in loss of the valine in the hydrophobic core, thereby affecting packing and orientation. A recent publication has identified activating JAK1 mutations selected for by cytokine deprivation. Interestingly, some of these mutations also confer resistance to the JAK inhibitors CMP6 and ruxolitinib.

We hypothesize that this relapse may be due mutations in the JAK2 kinase domain that prevent inhibitor binding, as is the case with IM-treated BCRABL. Using a random mutagenesis approach, we have identified JAK2 kinase domain residues critical in evading small-molecule inhibition. Here we describe the identification and characterization of mutations in the JAK2 kinase domain that confer resistance to the presence of small-molecule inhibitors in vitro. Inhibitor resistance is currently one of the biggest challenges facing Doxorubicin Topoisomerase inhibitor effective treatment of CML. Evidence Staurosporine suggests that BCRABL mutations are present at the commencement of treatment, and the inhibitor provides strong selective pressure for affected clone outgrowth and consequent patient relapse. Considerable effort has been put forth in identifying and testing new generations of inhibitors targeting specific BCR-ABL mutations. The in vitro prediction of BCR-ABL mutations against multiple inhibitors was robust and provided the field with significant data to aid in the design of second and third generation kinase inhibitors. Identification of a single point mutation, JAK2 V617F, thought to play an important role in MPN development and progression, initiated the search for small-molecule inhibitors of the JAK2 tyrosine kinase. We hypothesized that inhibitor-resistant JAK2 alleles may become apparent as large cohorts of MPN patients progress through clinical trials testing JAK2-selective drug therapies. The objective of our study was to identify JAK2 mutations that provide resistance to small molecule inhibitors before patient relapse is observed in the clinic. Some variation in the activation of Stat5, Akt and Erk1/2 was observed in the absence of inhibitors with the inhibitor-resistant mutants. TEL-JAK2 mutants with elevated basal phosphorylation of downstream signaling components correlated with lower in vitro kinase activity. For example, TELJAK2 V881A had high Erk2 phosphorylation in the absence of JAK Inhibitor-I, but weak kinase activity upon drug addition. We also examined growth ability in the presence of two clinically relevant inhibitors, TG101348 and CEP-701. The lack of growth difference observed in the XTT data suggests we have isolated compound-specific, not ATP competitor-specific, mutations. To further understand how the JAK2 kinase domain has been modified by the presence of mutations, we developed a novel intracellular assay to directly assess its phosphorylation ability in a system more relevant than a standard in vitro kinase assay.